GLP-1RAs and opioid use disorder: a new frontier in addiction treatment
Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...
Many adults stop GLP-1 therapy within a year with low restart rates, analysis finds
A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...
Monthly Prescribing Reference22h
Many With Overweight, Obesity Discontinue GLP-1 Receptor Agonists Within One Year
HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...
Daily22h
Consensus on Peri-Op Management of GLP-1, GIP, & SGLT-2 Inhibitors released
UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...
Zacks Small Cap Research on MSN23h
RANI: Impressive Bioavailability for RT-116
RANI READ THE FULL RANI RESEARCH REPORT On February 5th, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of ...
Cochrane23h
Does treatment with GLP-1 receptor agonists prevent complications for people with chronic kidney disease and diabetes?
• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...